Diabetic Foot Ulcer
      
                                Disease Overview
      
                    Image
              
Image
              
GAP IN TREATMENT OPTIONS
      
                        Current Standard Of Care
      
                        Image
              Debridement
      
                                    
            Debridement should be carried out in all chronic wounds to remove surface debris and necrotic tissues.
      
                                Image
              Off-loading
      
                                    
            Off-loading of the ulcer area is extremely important for the healing of plantar ulcers.
      
                                Image
              Dressings
      
                                    
            Ulcers heal more quickly and are often less complicated by infection when in a moist environment.
      
                                Image
              Bioengineered Skin Substitutes
      
                                    
            Accumulating evidence shows that bioengineered skin substitutes may be a promising therapeutic adjunct therapy to standard wound care.
      
                                Image
              MMP Modulators
      
                                    
            Matrix metalloproteinases regulate the extracellular matrix components.
      
                                The management of DFU remains a major therapeutic challenge which implies an urgent need to review strategies and treatments.
      
                                DIABETIC FOOT ULCER
      
            Mechanism of Action
      
              Anti-inflammatory, angiogenic and wound healing properties of MSCs are key to successfully treat patients with DFU
Image
              Clinical Trial Design
      
                Phase 3 - A Label extension, Randomized, Double Blind, Placebo Controlled, Multicentre, Single Dose, Phase III Study Assessing the Efficacy and Safety of Peri-ulcer Administration of Stempeucel® (Adult Human Bone Marrow Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells) in Patients with Non-Healing Diabetic Foot Ulcer
- Proportion of patients with complete healing / closure of the target ulcer at any time during the 12 week treatment period with sustained complete closure for 12 additional weeks of follow-up (Time frame: 12+12= 24 weeks)
 - Rate of reduction in size of the target ulcer
 
- Proportion of patients with at least 50% closure of target ulcer during the 24 weeks period
 - Proportion of patients with complete healing / closure of the target ulcer at any time during the 24 week follow up period
 
            Product Development Status
      
                Diabetic Foot Ulcer
      
Indication
      
Basic R&D
      
Pre-Clinical
      
Phase 1
      
Phase 2
      
Phase 3
      
Marketing Authorization
      
                                
Current status of Clinical Trials: All clinical trials are approved by DCGI in India